105 related articles for article (PubMed ID: 8230817)
1. [Accumulation of a disopyramide metabolite in renal failure].
Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of a disopyramide metabolite in renal failure.
Inagaki Y; Amano I; Otsu T
ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
[TBL] [Abstract][Full Text] [Related]
3. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
[TBL] [Abstract][Full Text] [Related]
4. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
[TBL] [Abstract][Full Text] [Related]
6. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
8. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Pike E; Lunde PK
Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
[TBL] [Abstract][Full Text] [Related]
9. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
Toy W; Sasyniuk BI
J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
12. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of vitamin E metabolites in the blood of renal failure patients.
Galli F; Floridi AG; Floridi A; Buoncristiani U
Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
[TBL] [Abstract][Full Text] [Related]
14. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.
Echizen H; Kawasaki H; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1993 Mar; 264(3):1425-31. PubMed ID: 8450476
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
[TBL] [Abstract][Full Text] [Related]
17. A simple method for the simulation of unbound serum disopyramide concentration in patients.
Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
[TBL] [Abstract][Full Text] [Related]
19. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis.
Burmeister JE; Scapini A; da Rosa Miltersteiner D; da Costa MG; Campos BM
Nephrol Dial Transplant; 2007 Apr; 22(4):1184-9. PubMed ID: 17272314
[TBL] [Abstract][Full Text] [Related]
20. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
